Addition of Rituximab to Chemotherapy Reduced the Rate of Surgery for Gastric-DLBCL Without Increasing Early Mortality

作者：Prouet Philippe^*; Giri Smith; Wiedower Eric; Fintel Andrew; Yaghmour George; Lamb Elena Paulus; Deneve Jeremiah; Fleming Martin; Dickson Paxton; Chandler Jason C; Martin Mike G

来源：Anticancer Research, 2017, 37(2): 813-817.

DOI：10.21873/anticanres.11382

• Neoplasia
• lymphoma
• chemotherapeutic/immuno-therapeutic approaches
• prognostication

Background: We evaluated surgical trends for gastric diffuse large B-cell lymphoma (gDLBCL) before and after the approval of rituximab and whether an association of early mortality existed in patients treated after approval of rituximab. Patients and Methods: We utilized the Surveillance Epidemiology and End Results (SEER) 18 database to extract data on patients with gDLBCL diagnosed between 1983-2012. Primary site-specific cancer-directed surgery using SEER sitespecific surgical codes and annual trends were analyzed. Patients were analyzed before and after 2006, the year rituximab gained U.S. Food and Drug Administration approval. Results: Joinpoint trend analysis showed the sharpest decline in surgical rates between 2000-2010. Adjusted surgical rates computed using poisson regression declined from 54.4% in 1983 to 6.9% in 2012, with an annual percentage change of -8.9% (95% confidence interval= - 9.7% to -8.3%; p-value < 0.01). No significant mortality increase at 30 and 60 days was found. Conclusion: While rituximab appears to have significantly changed how surgery is utilized for patients with gDLBCL, early mortality was unchanged.

• 出版日期2017-2